PolyNovo (ASX:PNV) logged a total monthly revenue of AU$12.4 million in March, up nearly 49% compared with the same time in 2024, according to a Wednesday filing with the Australian bourse.
Commercial sales climbed over 71% to AU$11.9 million. This was buoyed by record monthly sales of AU$9.3 million in the US, a 93% increase on the year-ago period.
Sales in the year to March surged 31% to AU$84.4 million.
In the same filing, the company said it has roughly 10 months of inventory on hand in the US and does not expect a material impact from the US tariffs based on preliminary assessment.
The medical device company's shares were down 8% in recent trade.